Hcw Biologics Inc (HCWB)

$0.27 -0.03 (-10.70%)
Market Cap 942,000.00
Revenue (ttm) 2.57M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,168.09%
Debt to Equity Ratio -3.23
Volume 775,400
Avg Vol 10,126,177
Day's Range N/A - N/A
Shares Out 3.52M
Stochastic %K 4%
Beta 0.90
Analysts Strong Sell
Price Target $2.00

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is i...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 842 2024
Fax: 954 842 2037
Address:
2929 North Commerce Parkway, Miramar, United States
Pennywarehouse
Pennywarehouse Apr. 4 at 1:20 AM
$HCWB Hey folks another Long dead micro penny shares Co Hcmc is about to pop up big time ; CEO secured $ 5 million dollar Loan to Revitalize the Hcmc ; Currently sitting all time Low at .00001 . All time high was.0065 in Feb 2021 . Check it out !
0 · Reply
le_ghoast
le_ghoast Apr. 2 at 2:42 PM
$GV it's over, time to move to $HCWB
1 · Reply
Flowjob
Flowjob Apr. 1 at 2:58 PM
$HCWB Trial started in november'25 data due within 30-45 days imo.
1 · Reply
focafoca99
focafoca99 Apr. 1 at 1:36 AM
$HCWB's main operational update is that HCW9302 has moved into first-in-human testing in alopecia areata, with up to 30 patients planned in the Phase 1 study.
1 · Reply
todd49
todd49 Mar. 31 at 10:49 PM
$HCWB financials came out..there’s definitely some good things happening! https://www.globenewswire.com/news-release/2026/03/31/3266126/0/en/HCW-Biologics-Reports-Fourth-Quarter-2025-and-Fiscal-Year-2025-Business-Highlights-and-Financial-Results.html
0 · Reply
algo888
algo888 Mar. 31 at 3:42 PM
$HCWB admit it... its pure garbage.. told you to load up on AIFF @ 1.90 now almost breaking above 2.40
0 · Reply
Pennywarehouse
Pennywarehouse Mar. 30 at 8:41 PM
$HCWB Quarterly Report ? Any news or comments Any body! Please.
0 · Reply
algo888
algo888 Mar. 30 at 12:58 PM
$HCWB stop dreaming, reason 90% of longs lose.. move to AIFF now... $$$$
0 · Reply
Pennywarehouse
Pennywarehouse Mar. 30 at 12:34 AM
$HCWB This is going up to full throttle above $ 1.50 in Pre-market on even a Fair quarterly Report and Future medicines in pipeline. $$$$$$ time to make Mega money.
0 · Reply
lookgoodplaygood22
lookgoodplaygood22 Mar. 28 at 4:38 PM
$HCWB $JTAI $SHPH I think we see 30-40% on $SHPH Monday. Just returning levels before pre dump Friday where the market took a dump.
0 · Reply
Latest News on HCWB
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

Mar 31, 2026, 5:05 PM EDT - 4 days ago

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

Mar 17, 2026, 7:50 AM EDT - 19 days ago

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

Mar 16, 2026, 8:00 AM EDT - 20 days ago

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

Mar 2, 2026, 8:00 AM EST - 4 weeks ago

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Feb 17, 2026, 9:50 PM EST - 6 weeks ago

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

Feb 13, 2026, 8:30 AM EST - 7 weeks ago

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nov 18, 2025, 7:25 AM EST - 4 months ago

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 14, 2025, 4:44 PM EST - 5 months ago

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 7, 2025, 7:00 AM EST - 5 months ago

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

HCW Biologics to Participate in the 2025 Maxim Growth Summit

Oct 16, 2025, 9:25 AM EDT - 6 months ago

HCW Biologics to Participate in the 2025 Maxim Growth Summit

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep 30, 2025, 8:45 AM EDT - 6 months ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep 18, 2025, 9:15 AM EDT - 7 months ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Sep 16, 2025, 8:00 AM EDT - 7 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

Aug 25, 2025, 9:53 AM EDT - 7 months ago

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Aug 25, 2025, 8:00 AM EDT - 7 months ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 18, 2025, 2:44 PM EDT - 8 months ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 27, 2025, 7:45 AM EDT - 10 months ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 26, 2025, 7:55 AM EDT - 10 months ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

Jun 4, 2025, 8:20 AM EDT - 10 months ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 6:14 PM EDT - 11 months ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:01 PM EDT - 11 months ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:30 AM EDT - 11 months ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Announces 1-for-40 Reverse Stock Split

Apr 1, 2025, 4:35 PM EDT - 1 year ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 3:30 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Mar 6, 2025, 6:55 AM EST - 1 year ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Feb 3, 2025, 7:15 AM EST - 1 year ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Jan 15, 2025, 7:00 AM EST - 1 year ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Dec 23, 2024, 8:10 AM EST - 1 year ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 9:27 PM EST - 1 year ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Why Is Penny Stock HCW Biologics Surging On Monday?

Nov 18, 2024, 10:15 AM EST - 1 year ago

Why Is Penny Stock HCW Biologics Surging On Monday?

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 18, 2024, 7:00 AM EST - 1 year ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 4:40 PM EST - 1 year ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 23, 2024, 4:30 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 4:35 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 2 years ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Apr 1, 2024, 4:10 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 8, 2023, 7:30 AM EST - 2 years ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Sep 6, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Jun 14, 2023, 7:30 AM EDT - 3 years ago

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

May 9, 2023, 7:15 AM EDT - 3 years ago

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Apr 27, 2023, 7:40 AM EDT - 3 years ago

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Apr 13, 2023, 7:15 AM EDT - 3 years ago

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Apr 3, 2023, 8:13 AM EDT - 3 years ago

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 4:25 PM EDT - 3 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

HCW Biologics Enters CRADA with National Cancer Institute

Dec 8, 2022, 7:55 AM EST - 3 years ago

HCW Biologics Enters CRADA with National Cancer Institute

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Dec 7, 2022, 7:30 AM EST - 3 years ago

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Nov 8, 2022, 7:00 AM EST - 3 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Pennywarehouse
Pennywarehouse Apr. 4 at 1:20 AM
$HCWB Hey folks another Long dead micro penny shares Co Hcmc is about to pop up big time ; CEO secured $ 5 million dollar Loan to Revitalize the Hcmc ; Currently sitting all time Low at .00001 . All time high was.0065 in Feb 2021 . Check it out !
0 · Reply
le_ghoast
le_ghoast Apr. 2 at 2:42 PM
$GV it's over, time to move to $HCWB
1 · Reply
Flowjob
Flowjob Apr. 1 at 2:58 PM
$HCWB Trial started in november'25 data due within 30-45 days imo.
1 · Reply
focafoca99
focafoca99 Apr. 1 at 1:36 AM
$HCWB's main operational update is that HCW9302 has moved into first-in-human testing in alopecia areata, with up to 30 patients planned in the Phase 1 study.
1 · Reply
todd49
todd49 Mar. 31 at 10:49 PM
$HCWB financials came out..there’s definitely some good things happening! https://www.globenewswire.com/news-release/2026/03/31/3266126/0/en/HCW-Biologics-Reports-Fourth-Quarter-2025-and-Fiscal-Year-2025-Business-Highlights-and-Financial-Results.html
0 · Reply
algo888
algo888 Mar. 31 at 3:42 PM
$HCWB admit it... its pure garbage.. told you to load up on AIFF @ 1.90 now almost breaking above 2.40
0 · Reply
Pennywarehouse
Pennywarehouse Mar. 30 at 8:41 PM
$HCWB Quarterly Report ? Any news or comments Any body! Please.
0 · Reply
algo888
algo888 Mar. 30 at 12:58 PM
$HCWB stop dreaming, reason 90% of longs lose.. move to AIFF now... $$$$
0 · Reply
Pennywarehouse
Pennywarehouse Mar. 30 at 12:34 AM
$HCWB This is going up to full throttle above $ 1.50 in Pre-market on even a Fair quarterly Report and Future medicines in pipeline. $$$$$$ time to make Mega money.
0 · Reply
lookgoodplaygood22
lookgoodplaygood22 Mar. 28 at 4:38 PM
$HCWB $JTAI $SHPH I think we see 30-40% on $SHPH Monday. Just returning levels before pre dump Friday where the market took a dump.
0 · Reply
El_Grande_Sniper
El_Grande_Sniper Mar. 28 at 4:31 PM
$JTAI $HCWB $SHPH is my watchlist for next week, one of them will be a huge winner at some point.
1 · Reply
acarsoy
acarsoy Mar. 27 at 8:41 PM
$HCWB next week’s runner?!
0 · Reply
El_Grande_Sniper
El_Grande_Sniper Mar. 27 at 7:12 PM
$HCWB This will do between 300 and 600% next week.
2 · Reply
El_Grande_Sniper
El_Grande_Sniper Mar. 27 at 6:13 PM
$HCWB This shit is low-key building. Mega runner in a few days. First target $1.18 then $1.65 and $1.90
1 · Reply
algo888
algo888 Mar. 26 at 6:54 PM
$HCWB alerted bag hokders here on AIFF @ 1.90 15 min at opening now @ 2.88 OH well I tried
1 · Reply
todd49
todd49 Mar. 26 at 6:21 PM
$HCWB guess the asses found more shares to give away
0 · Reply
SexArePee
SexArePee Mar. 26 at 4:18 PM
$HCWB Just movin under the radar now. Back to 0.50 - .75
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 26 at 3:04 PM
$HCWB first green candle
0 · Reply
algo888
algo888 Mar. 26 at 2:48 PM
$HCWB you like losing all ur lifesavings fool? Buy AIFF to turn your losing streak around LOL
0 · Reply
SexArePee
SexArePee Mar. 26 at 2:08 PM
$HCWB .50
0 · Reply
SexArePee
SexArePee Mar. 25 at 8:16 PM
$HCWB cute drop now bounce.
1 · Reply
Pennywarehouse
Pennywarehouse Mar. 25 at 7:54 PM
$HCWB They are coming out with exceptionally positive quarterly Report With many pipeline Approvals and Future plans ; Loaded
1 · Reply